Kenneth Avocetien

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas et al. · Cancer Research · 2020 · 25 citations

Pharmacy, Immunology, Oncology +16

<i>De Novo</i>Asymmetric Synthesis of Phoracantholide J

Kenneth Avocetien, Jiazhen J. Li, Xiaofan Liu et al. · Organic Letters · 2016 · 24 citations

Pharmacy, Chemistry, Medicinal Chemistry +11

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2021 · 24 citations

Pharmacy, Oncology, Pharmacology +17

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

Shawn P. Fessler, Anouk Dirksen, Scott D. Collins et al. · Cancer Research · 2020 · 11 citations

Pharmacy, Oncology, Pharmacology +16

Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios

Susan M. Clardy, Alex Uttard, Bingfan Du et al. · Molecular Cancer Therapeutics · 2023 · 10 citations

Pharmacy, Pharmaceutics, Pharmacology +17